Exercise enhanced first-line combination treatment of Lenvatinib plus ICI (anti-PD-1) in patients with unresectable hepatocellular carcinoma by fostering a shift of TME towards anti-tumoral with improved OS, progression-free survival (PFS) and overall response rate (ORR) [158]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.